What Research Shows About Tysabri PML Risk After Treatment Ends

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Medical Risks

If you or a loved one developed progressive multifocal leukoencephalopathy after stopping Tysabri, understanding the timeline and risk factors is critical. The medical community has long recognized that certain biologic therapies carry rare but serious infection risks, and ongoing studies continue to refine our knowledge. This page summarizes current evidence on PML associated with Tysabri use, including what the science says about post-treatment monitoring and symptom recognition.

The Bridge: From General Knowledge to Tysabri and PML

The transition from general health awareness to specific medical-legal concern becomes critical when considering the complexities surrounding Tysabri (natalizumab) and its association with PML. Tysabri is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of PML, a severe opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has mandated a boxed warning on the Tysabri label to highlight this risk, emphasizing that healthcare professionals should monitor patients for any new signs or symptoms suggestive of PML and withhold Tysabri dosing immediately at the first indication of the condition (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis of PML

The clinical presentation of PML can be subtle and variable, often mimicking other neurological conditions. Patients may experience progressive weakness, visual disturbances, cognitive decline, or coordination problems. Diagnosis typically relies on brain imaging, such as MRI, and detection of JCV DNA in cerebrospinal fluid. A retrospective national cohort study of 456 PML cases observed between 1987 and 2024 described the demographic, clinical, radiological, and laboratory characteristics of the disease, noting that survival and presentation have changed over time depending on the underlying condition (https://pubmed.ncbi.nlm.nih.gov/40922664/). This underscores the importance of early recognition and intervention in Tysabri-treated patients.

Pharmacological Mechanism and Risk Factors

The pharmacological mechanism linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. By blocking the adhesion of immune cells to the blood-brain barrier, Tysabri reduces the migration of lymphocytes into the central nervous system. While this effect is therapeutic for multiple sclerosis, it also impairs immune surveillance against JCV, allowing the virus to reactivate and cause PML. The FDA label identifies three key risk factors for PML development in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy, weighing the expected benefit against the risk of PML.

Clinical Trial Data and Incidence

In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1,869 multiple sclerosis patients treated for a median of 120 weeks, both of whom had also received interferon beta-1a. The third case occurred after eight doses in one of 1,043 Crohn's disease patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These data highlight that PML can occur even with relatively short exposure, though risk increases with longer treatment duration. Given the severity of PML, the adequacy of warnings regarding Tysabri and PML is a critical concern.

Regulatory Warnings and Legal Considerations

The FDA has required a boxed warning and a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure that patients and healthcare providers are informed about the risks and that monitoring occurs (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, affected patients and their families may question whether these warnings were sufficient to prevent harm, particularly if PML developed despite adherence to monitoring protocols. Attorney-related considerations for affected patients include evaluating whether the drug manufacturer provided adequate risk information, whether healthcare providers followed recommended monitoring guidelines, and whether delays in diagnosis or treatment contributed to worse outcomes. The timeline between Tysabri exposure and documented harm is variable. PML can develop after a few doses or after years of treatment, as seen in clinical trial data where one case occurred after eight doses and others after longer exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The risk increases with treatment duration beyond two years, but cases have been reported earlier, particularly in patients with additional risk factors such as prior immunosuppressant use or positive anti-JCV antibody status (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability complicates risk assessment and underscores the need for ongoing vigilance.

Legal Recourse for Affected Patients

For patients who develop PML after Tysabri treatment, legal considerations may involve claims of inadequate warning or failure to monitor. The FDA label explicitly states that Tysabri increases the risk of PML and that healthcare professionals should monitor patients for new signs or symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). If a patient was not informed of these risks or if monitoring was not performed appropriately, there may be grounds for legal action. Additionally, the restricted distribution program is designed to mitigate risk, but its effectiveness depends on compliance by both prescribers and patients. In summary, Tysabri is associated with a significant risk of PML, a devastating brain infection. The FDA has mandated strong warnings and a restricted distribution program, but cases continue to occur. Patients and their families should be aware of the risk factors, clinical presentation, and the importance of prompt medical evaluation if symptoms arise. For those affected, legal counsel can help assess whether the warnings and monitoring were adequate and whether compensation may be available for harm suffered.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning for this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Key risk factors include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What legal options do I have if I developed PML after taking Tysabri?

You may have grounds for a claim if the drug manufacturer failed to provide adequate warnings or if your healthcare provider did not follow recommended monitoring guidelines. An attorney can evaluate your case and help seek compensation for your injuries.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.